Content area

|
|

Potentielle farmakologiske konsekvenser som følge af udviklingen i forbruget af opioider i Danmark

Forfatter(e)
Lona Christrup1 & Eva Aggerholm Sædder2 1) Institut for Lægemiddeldesign og Farmakologi, Københavns Universitet 2) Klinisk Farmakologisk Afdeling, Aarhus Universitetshospital Ugeskr Læger 2017;179:V01170077
Reference: 
Ugeskr Læger 2017;179:V01170077
Blad nummer: 
Sidetal: 
1160-1163
Potential pharmacological consequences of the development of the opioid consumption in Denmark
The total consumption of weak opioids (mainly of tramadol) in Denmark was doubled during the period 2001-2013. On the contrary, the total consumption of strong opioids remained almost constant in the same period. The increase in tramadol consumption is not rational, as it has no special benefits with regards to efficacy, side effects and abuse potential. The terms strong- and weak opioids are inappropriate, because it often erroneously is interpreted as if the weak opioids are safer, but it is really just a matter of potency: strong opioids are simply more potent.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Lars Guttorm | 14/01
5 kommentarer
af Morten Ellemose Gulev | 14/01
4 kommentarer
af Henning Damgaard Laugesen | 14/01
1 Kommentar
af Jette E. Hansen Kristiansen | 14/01
1 Kommentar
af Eva Pernille Due | 13/01
6 kommentarer
af Ole Faber | 11/01
1 Kommentar
af Niels Bentzon | 10/01
10 kommentarer